Kevin Gillis has joined Third Rock Ventures as chief financial officer. He previously was VP of finance at Coley Pharmaceutical Group. Former Third Rock CFO Anne-Mari Paster will serve as a consultant going forward. Third Rock is a Boston-based venture firm focused on life sciences opportunities.
Third Rock Ventures, L.L.C, a venture capital firm focused on launching leading life sciences companies, today announced the appointment of Kevin Gillis as Chief Financial Officer, overseeing the financial reporting, planning and analysis for the firm and its portfolio companies. Anne-Mari Paster, who initially served in this function, will continue to provide counsel and guidance to Third Rock Ventures within a consultant role.
“Kevin Gillis brings to Third Rock Ventures extensive financial and operating experience ranging from overseeing and managing development budgets for clinical programs to actively participating in an initial public offering and subsequent acquisition,” said Kevin Starr, partner of Third Rock Ventures. “We are delighted that Kevin will provide the benefit of his full range of experience and insight to not only our own firm, but to our portfolio companies as we launch, build and operate these great companies.”
Third Rock Ventures employs a unique model in which its team actively collaborates with entrepreneurs, initially filling key active management roles as needed to architect the right vision, operations, and culture to create companies that will make a difference in people's lives and ultimately deliver exceptional value.
Mr. Gillis has approximately 20 years of finance experience, successfully designing, overseeing and managing financial strategy, planning and analysis functions for both newly emerging and established biotech companies. Most recently, Mr. Gillis served as Vice President of Finance at Coley Pharmaceutical Group, assisting in the company's successful initial public offering in 2005, participating as an executive team member and overseeing the finances related to the company's acquisition by Pfizer in 2008. Prior to his tenure at Coley, Mr. Gillis served in a number of senior finance roles at Millennium Pharmaceuticals and The Coco-Cola Company. Mr. Gillis received his MBA from Bentley College and his BA from Brandeis University.
As a Partner at Third Rock, Mr. Gillis will drive the firm's overall financial operations, planning and analysis. Additionally, he will support the financial operations and planning efforts for the firm's entire portfolio including taking on senior finance roles for certain Third Rock portfolio companies.
“We are pleased that Anne-Mari Paster, who successfully designed and implemented Third Rock's initial infrastructure, is able to continue to provide expertise to the firm and our portfolio companies moving forward through an ongoing consulting relationship,” said Starr.
In addition to the new team member, Third Rock Ventures' partners include: Mark Levin founder and former CEO of Millennium Pharmaceuticals and four other biotech companies; Kevin Starr, active Board of Directors member of several biotech companies and former COO/CFO of Millennium; Robert Tepper, M.D., a scientific leader, biotech entrepreneur and previous head of R&D and CSO of Millennium; Lou Tartaglia, Ph.D., a thought leader in the field of obesity and previous General Manager and Head of New Ventures of Gene Logic and Millennium, respectively; Nick Leschly, an executive with experience in biotech drug development and marketing; and Cary Pfeffer, M.D., founder of the Pfeffer Group, a business development firm which successfully facilitated more than 30 collaborations for both newly emerging and established biotech companies. Additionally, Third Rock has two venture partners: Neil Exter, who most recently served as Chief Business Officer of Alantos Pharmaceuticals; and, Craig Muir who most recently served as Senior Vice President, Technical Operations for Codon Devices.
About Third Rock Ventures
Third Rock Ventures L.L.C. is a premier venture firm focused on life sciences investing and launching companies that make a difference in people's lives. The firm raised its first fund of $378 million in 2007. Collaborating with entrepreneurs, the Third Rock team applies its deep expertise to establish the roadmap and building blocks for rapidly-growing and highly-successful life sciences companies. The Third Rock team has a unique vision and experience in building great companies, extensive academic and industry networks and a collective track record for creatively managing the value creation path to deliver exceptional performance. For more information, please visit www.thirdrockventures.com.